The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Otsuka Starts PIII Trial of Rebamipide Ophthalmic Suspension in US
July 20, 2012
- Alfresa HD to Make Tokiwa Yakuhin Wholly-Owned Subsidiary
July 19, 2012
- OTC Market Decreases 0.4% to 611.5 Billion Yen in 2011: Fuji-Keizai
July 19, 2012
- Eisai Ties Up with Verastem for Generation of Novel Wnt Signal Inhibitors
July 19, 2012
- Chugai, Taisho File NDA for Novel Osteoporosis Treatment
July 19, 2012
- Chugai Opens Singapore Research Subsidiary, Aims to Produce Over 5 Antibody Candidates per Year
July 18, 2012
- Nippon Kayaku Initiates PIII Study of NK105 for Breast Cancer
July 18, 2012
- Chairman Humer of Roche Criticizes Drug Pricing Policy in Japan as“Extremely Negative”
July 18, 2012
- Nippon Kayaku Launches New Specification of Generic Kytril
July 18, 2012
- China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
- MSD to Launch Oral Rotavirus Vaccine RotaTeq on July 20
July 18, 2012
- Janssen Applies for HIV Drug Prezista Naive Tablet 800 mg
July 17, 2012
- Otsuka HD’s Vice Chairman Otake Resigns for “Personal Reasons”
July 17, 2012
- Bioventure Industry Caught in Negative Spiral: DBJ Report
July 17, 2012
- Cumulative Sales of Japan’s 1st Emergency Contraceptive NorLevo Nears 50,000 Packs in 1 Year
July 16, 2012
- RIJ Plans World’s First Trial of iPS Cell Therapy in Men: President & CEO Kagimoto
July 16, 2012
- Shionogi Announces Positive Results of Second PIII Study for Dolutegravir
July 13, 2012
- Daiichi Sankyo to Receive METI’s Grant for Its Biopharmaceutical Production Facility Expansion
July 13, 2012
- Astellas to Develop Companion Diagnostic Agents in Collaboration with Other Companies: President Hatanaka
July 13, 2012
- Yoshindo to Develop Biopharmaceutical Business in 3 Steps: President Shimomura
July 13, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…